NIOX Group Sets Date and Details for 2026 Annual General Meeting

Circassia Pharmaceuticals ( (GB:NIOX) ) has shared an update.

NIOX Group plc has published the notice for its 2026 Annual General Meeting, confirming that the AGM will take place on 21 May 2026 at the company’s registered office in Oxford. The notice and the 2025 Annual Report and Accounts are now available on the company’s investor website, with hard copies dispatched to shareholders who requested them.

The announcement provides logistical details for investors, including the requirement for shareholders wishing to attend the AGM in person to register their intention by a specified deadline. This scheduling and documentation update signals the formal start of NIOX’s annual governance cycle, giving shareholders an opportunity to review performance and engage with the board on strategy and oversight matters.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £86.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Spark’s Take on NIOX Stock

According to Spark, TipRanks’ AI Analyst, NIOX is a Neutral.

The score is primarily supported by strong financial quality (growth, profitability, low debt, and solid cash generation). It is held back by bearish technical signals (price below major moving averages and negative MACD) and a high P/E that is only partly offset by the dividend yield.

To see Spark’s full report on NIOX stock, click here.

More about Circassia Pharmaceuticals

NIOX Group plc is a UK-based medical diagnostics company focused on respiratory health. The group develops and supplies products used to measure airway inflammation, targeting healthcare providers and patients in asthma and related respiratory disease markets.

Average Trading Volume: 807,102

Technical Sentiment Signal: Sell

Current Market Cap: £235.8M

Find detailed analytics on NIOX stock on TipRanks’ Stock Analysis page.